Last updated on December 2018

Study of AMG 673 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia


Brief description of study

This is a first-in-human, open-label, phase 1, sequential dose escalation study. AMG 673 will be evaluated as a short term intravenous (IV) infusion in adult subjects with relapsed/refractory AML. The study will be conducted at approximately 7 sites in the United States, Australia and Germany.

Clinical Study Identifier: NCT03224819

Contact Investigators or Research Sites near you

Start Over

Amgen Call Center

Research Site
Parkville, Australia
7.01miles
  Connect »

Amgen Call Center

Research Site
Melbourne, Australia
7.28miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.